Hims & Hers debates ‘unresolved’ after earnings, says Morgan Stanley
Morgan Stanley notes that Hims & Hers beat in Q4 and guided Q1 and calendar year 2025 revenue significantly above the Street consensus.
Hosted on MSN6d
Morgan Stanley Downgrades Hims & Hers Health (HIMS)
Fintel reports that on February 18, 2025, Morgan Stanley downgraded their outlook for Hims & Hers Health (NYSE:HIMS) from ...
Morgan Stanley downgrades Hims & Hers on valuation concerns
Morgan Stanley downgraded Hims Hers Health Inc (NYSE:HIMS) to "Equal-weight" from "Overweight" as the stock’s recent strong performance leaves limited near-term upside, despite continued business ...
Piper Sandler Keeps Their Hold Rating on Hims & Hers Health (HIMS)
In a report released today, Korinne Wolfmeyer from Piper Sandler maintained a Hold rating on Hims & Hers Health (HIMS – Research Report), ...
Seeking Alpha6d
Hims & Hers downgraded at Morgan Stanley on recent rally
Morgan Stanley downgraded telehealth firm Hims & Hers Health (NYSE:HIMS) to Equal Weight from Overweight on Tuesday ahead of its Q4 2024 results next week, citing the stock’s recent rally.
Hims & Hers Health (NYSE:HIMS) Downgraded by Morgan Stanley to Equal Weight
Morgan Stanley cut shares of Hims & Hers Health (NYSE:HIMS – Free Report) from an overweight rating to an equal weight rating ...
Smart Money Is Betting Big In HIMS Options
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions ...